Cargando…
Gene Expression Profile and Acute Gene Expression Response to Sclerostin Inhibition in Osteogenesis Imperfecta Bone
Sclerostin antibody (SclAb) therapy has been suggested as a novel therapeutic approach toward addressing the fragility phenotypic of osteogenesis imperfecta (OI). Observations of cellular and transcriptional responses to SclAb in OI have been limited to mouse models of the disorder, leaving a paucit...
Autores principales: | Surowiec, Rachel K, Battle, Lauren F, Schlecht, Stephen H, Wojtys, Edward M, Caird, Michelle S, Kozloff, Kenneth M |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7422710/ https://www.ncbi.nlm.nih.gov/pubmed/32803109 http://dx.doi.org/10.1002/jbm4.10377 |
Ejemplares similares
-
Gender-Related Impact of Sclerostin Antibody on Bone in the Osteogenesis Imperfecta Mouse
por: Cardinal, Mickaël, et al.
Publicado: (2021) -
THU455 Sclerostin Inhibitor Use In The Medical Management Of Osteogenesis Imperfecta Type III
por: Lundholm, Michelle Diane, et al.
Publicado: (2023) -
Effect of sclerostin inactivation in a mouse model of severe dominant osteogenesis imperfecta
por: Marulanda, Juliana, et al.
Publicado: (2023) -
Therapeutic aptamer targeting sclerostin loop3 for promoting bone formation without increasing cardiovascular risk in osteogenesis imperfecta mice
por: Wang, Luyao, et al.
Publicado: (2022) -
A systematic review and meta-analysis on the efficacy of stem cell therapy on bone brittleness in mouse models of osteogenesis imperfecta
por: Battle, Lauren, et al.
Publicado: (2021)